Tisagenlecleucel
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- February 2019
Comments
RED
- NICE TA554 - relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. (Decision date - Feb 2019)
DNP:
- NICE TA842 - treating follicular lymphoma after 2 or more therapies. Terminated
appraisal. (Decision date - December 2022)
- NICE TA933 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. Terminated appraisal, replaces NICE TA567 (Decision - December 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again